Vellano, Christopher P.

BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 444

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., et al. (2019) · Scientific Reports

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 253

RGS14 is a natural suppressor of both synaptic plasticity in CA2 neurons and hippocampal-based learning and memory

Lee, S. E., Simons, S. B., Heldt, S. A., Zhao, M., Schroeder, J. P., Vellano, C. P., Cowan, D. P., Ramineni, S., Yates, C. K., Feng, Y., et al. (2010) · Proceedings of the National Academy of Sciences

Neuroscience and Neuropharmacology ResearchMemory and Neural Mechanisms

Cited by 224

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C. A., Albrecht, C., Alpar, D., Arnhof, H., Bergner, O., Bosch, K., et al. (2024) · Nature Cancer

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 76

Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Gerlach, D., Gmachl, M., Ramharter, J., Teh, J., Fu, S.-C., Trapani, F., Kessler, D., Rumpel, K., Botesteanu, D.-A., Ettmayer, P., et al. (2020) · Cancer Research

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 53

Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Savarese, F., Gollner, A., Rudolph, D., Lipp, J., Popow, J., Hofmann, M. H., Arnhof, H., Rinnenthal, J., Trapani, F., Gmachl, M., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 25

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

Hofmann, M. H., Lu, H., Duenzinger, U., Gerlach, D., Trapani, F., Machado, A. A., Daniele, J. R., Waizenegger, I., Gmachl, M., Rudolph, D., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 20